Adrian Goldis

TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.

TL;DR: The estimate of HBV prevalence in 2016 differs from previous studies, potentially because it took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time.

TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.

TL;DR: Whether an East–West gradient in the incidence of inflammatory bowel disease in Europe exists is investigated to find out whether international guidelines for diagnosis and initial treatment are not being followed uniformly by physicians.

TL;DR: The EU is uniquely poised to eliminate HCV; however, expansion of screening programmes is essential to increase treatment to achieve the WHO targets, and a united effort, grounded in sound epidemiological evidence, will also be necessary.